CSL Limited (ASX: CSL)
The first blue chip ASX share to consider is CSL. It is one of the world’s leading biotechnology companies, comprising two businesses – CSL Behring and Seqirus. CSL Behring is the number one player in a global plasma therapies industry worth a massive US$30 billion per year. Whereas Seqirus is the number two player in the US$6 billion global influenza vaccines industry. CSL has been tipped for solid long term growth thanks to increasing demand for its therapies and its lucrative R&D pipeline.
UBS is positive on CSL. It currently has a buy rating and $330.00 price target on its shares.
UBS positive on
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$303.99 |
Change
0.890(0.29%) |
Mkt cap ! $147.1B | |||
| Open | High | Low | Value | Volume |
| $302.12 | $305.00 | $300.79 | $155.5M | 515.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 330 | $303.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $304.25 | 386 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |